Organic Active Ingredients TRIZ Cases

Novel pyridone compounds enhance metabolic stability and binding affinity to the c-Met enzyme through targeted structural modifications.

Aqueous thixotropic spray uses microcrystalline cellulose to coat mucosal membranes with high shear viscosity.

Spiro aryl isoxazoline derivatives inhibit 5-lipoxygenase to reduce chronic airway inflammation.

Polyurethane additives prevent phenyl acetone formation, maintaining amphetamine stability in transdermal patches.

Imidazo[1,2-a]pyrazine compounds inhibit the CK2 enzyme to overcome drug resistance in cancer cells.

RNA interference agents silence alpha-mannosidase 2 and Cadherin87A genes, reducing viral load and blocking dengue transmission.

Optimized TLR8 agonists enhance immune responses in neonates and elderly subjects by balancing efficacy with safety profiles.

Administering pridopidine as a Sigma-1 receptor agonist enhances BDNF secretion, addressing inadequate neuroprotective modulation in current treatments.

Formula I compounds modulate KRAS activity to overcome challenges targeting mutant proteins in cancer therapy.

Administering PIP2-stabilizing compounds restores cerebral blood flow and functional hyperemia in CADASIL by modulating Kir2.1 channels.

Administering L-methylfolate treats optic disorders by bypassing enzymatic conversion bottlenecks in patients with folate cycle malfunctions.

A nucleic acid construct uses guide RNA to bind target RNAs and an RNA-cleaving Cas protein to reduce expression in targeted cells.

Replacing calcium salts with bivalent metal oxides increases phosphatidylserine yield to 90% while lowering production costs.

Core-to-surface polymerization reduces ruthenium catalyst impurities below 450 ppm while enabling pharmaceutical agent incorporation.

Modified imidazole structures deliver anesthesia while preserving adrenocortical hormone synthesis, resolving the trade-off between efficacy and adrenal safety.

Granular pantoprazole particles enable direct compression, eliminating heat-induced degradation during drying.

S1P and ATX modulating agents target specific molecular pathways to promote myelination.

Immobilization particles use spacer structures to bind pathogens, preserving microbiome balance and preventing autoimmune reactions.

Nasal DIMEB delivery bypasses the blood-brain barrier via olfactory nerves, avoiding pulmonary toxicity from systemic dosing while inhibiting prion aggregation.

An injectable ethyl cellulose gel depot prevents drug leakage from tumor cracks while enabling image-guided photodynamic therapy.

Cis-configured morpholine derivatives resolve metabolic stability issues in somatostatin receptor 4 agonists, achieving high potency and brain penetration.

Flash-freezing cannabinoid mixtures with liquid nitrogen creates spreadable pastes that mitigate cholesterol risks from traditional butter production.

Cationic carrier units form micelles to shield polynucleotides from nuclease degradation while enabling transmembrane transport.

Combining EGFR, MEK, and CDK inhibitors treats BRAF mutation cancers without BRAF inhibitors.

Orally disintegrating baclofen composition overcomes poor absorption by utilizing crospovidone and F-MELT excipients to achieve rapid breakdown.

CAR-T cells targeting CT45 overcome chemotherapy resistance in aggressive ovarian cancer.

Fermentation alcohol precipitates ginseng polysaccharides, isolating specific sugar compositions that enhance immune function.

CHRNB3 inhibitors reduce smoking frequency by targeting genetic variants to address underlying addiction mechanisms.

AIM protein addresses non-alcoholic steatohepatitis pathology using high-fat diet knockout mice to replicate human metabolic syndrome conditions.

Replacing water with ethanol and polyethoxylated derivatives enables high-concentration melatonin solubility without degradation or precipitation.

A biodegradable dextran matrix releases polysaccharide to inhibit cell migration and prevent post-surgical adhesion formation.

Antibodies neutralize sclerostin to stimulate bone formation, overcoming limited efficacy of resorption inhibitors.

Combining eIF5A and Notch inhibitors enriches regulatory T cells to protect pancreatic beta cells from immune destruction in Type 1 diabetes.

Guanidine hydrochloride disrupts hydrogen bonds to block macromolecule uptake, inhibiting rapid cancer cell proliferation.

S-substituted amino mercaptopropionate derivatives release hydrogen sulfide to provide neuroprotective effects.

Benzofuran bicyclic benzamide compounds target the HCV NS5B enzyme, resolving toxicity issues found in prior therapies.

Formula I compounds inhibit non-phagytic NADPH oxidase isoforms to lower ROS levels while preserving immune cell function.

Guanidinium macromolecules with monosaccharide targeting moieties selectively kill multidrug-resistant bacteria while minimizing mammalian cell toxicity.

Low-temperature deposition of viscous filling into a setting gelatinous shell prevents active ingredient decomposition and leakage without foam layers.

Novel FXR agonist compounds modulate farnesoid X receptor activity, addressing insufficient therapeutic outcomes in existing treatments.

Pharmacological formulation strengthens ciliary muscle contraction to enhance accommodation and increase depth of focus.

Inhalation bypasses gastrointestinal absorption variability to stabilize plasma levels and reduce motor fluctuations in Parkinson's disease.

Gamma-amino alcohol derivatives block transporter proteins to prevent rapid reuptake, maintaining optimal signaling precision and reducing side effects.

A SN-38 poly(amino acid) block copolymer formulation enhances aqueous solubility for cancer therapy.

Dihydropyrimidinoisoquinolinones block GPR84 to reduce neuroinflammation in multiple sclerosis.

Cordyceps compounds regulate tumor gene methylation to restore suppressor expression, reducing conventional drug dosages and side effects.

Radiolabeled ligands quantify GluA1 receptors to replace subjective symptom checklists with objective diagnostic data.

Macroporous resin purification enriches dLGG in the extract to inhibit cancer cell growth and achieve synergistic effects with chemotherapeutic agents.

Small molecules target PRC1 and MLL complexes to restore ciliated cells, addressing inefficient mucociliary clearance in COPD.

Synthetic epidithiodiketopiperazine analogues modify chemical structures to enhance solubility and stability, addressing toxicity issues in cancer treatment.

Enveloped virus-like particles vectorize cyclic dinucleotides via fusogenic glycoprotein membrane fusion.

Dry powder pharmaceutical compositions stabilize biologic molecules using specific excipients and buffers for room temperature storage.

Single heterocyclic GLP-1 agonist compounds reduce treatment complexity by simultaneously stimulating insulin secretion and suppressing glucagon release.

Combining chlorhexidine with sodium pentaborate overcomes viral resistance to existing drugs while minimizing cytotoxicity.

Identifying FIG-ROS fusion proteins via specific probes resolves the contradiction between broad chemotherapy side effects and precise therapeutic targeting.

A hypotonic composition containing sodium deoxycholate and hyaluronidase for selective fat cell disruption.

Liquid microreservoirs in a polysiloxane matrix dissolve capsaicin below saturation to increase flux into nerve fibers for neuropathic pain relief.

A base-editing system integrates a non-protein uracil-DNA glycosylase inhibitor to block enzyme activity and preserve cytidine deamination products.

Biodegradable polymeric cores encapsulate agents while PEG layers extend circulation half-life, resolving selectivity and stability trade-offs.

A fermented formula combined with non-digestible oligosaccharides enhances rotavirus particle binding.

Bedtime estrogen and melatonin administration resolves the contradiction between effective symptom relief and increased mammary cancer incidence.

Selective binding to the mutant substrate pocket reduces cancer cell proliferation while sparing wild-type EZH2 activity.

A cross-linked citrate-presenting polymer network promotes bone growth by up-regulating osterix and alkaline phosphatase gene expression.

Metyrapone blocks Cyp11a1 enzyme activity to reduce immunosuppressive glucocorticoids, reversing T cell dysfunction and enhancing anti-tumor immunity.

Synthesizing an azo dye derivative with sulfonic acid groups to deliver potent antioxidant activity comparable to vitamin C.

Optimized amphipathic peptides form stable nanocomplexes that deliver plasmid DNA with high efficiency while minimizing cytotoxicity.

Selective cyanocyclopropyl inhibitors target Cathepsin K to reduce bone degradation in osteoporosis without toxicity.

A combination therapy regimen using a selective JAK1 inhibitor, an immunomodulatory agent, and a steroid to treat hematological diseases.

Liver-derived untranslated regions extend mRNA half-life and boost protein synthesis rates to overcome instability bottlenecks.

Ethyl cellulose hydrophobic matrix maintains naloxone-to-oxycodone ratio, preventing euphoric effects from intravenous abuse.

Coupling agents activate valine to bypass protection steps, simplifying purification and boosting yield.

Dual-action tetrahydropyrimidodiazepines combine alpha2δ-1 binding with NET inhibition to treat chronic pain while reducing side effects.

Selective pyrazole compounds reduce lesion volume while maintaining ovarian estrogen secretion and bone density.

A gout formulation combines celery extract, cherry extract, and lithium salt to target uric acid metabolism.

Isolated neural stem cell microparticles inhibit glioblastoma migration, resolving safety risks of live cells while maintaining therapeutic efficacy.

CD44-targeted nanocarriers concentrate radiation enhancers at the tumor site, reducing damage to surrounding healthy brain tissue.

Therapeutic double-stranded RNA eliminates persistent fatigue and cognitive impairment after SARS-CoV-2 infection by targeting residual viral activity.

A hyaluronic acid gel mixture combines monophasic and biphasic components to enhance viscoelasticity.

A porous implantable device releases therapeutic agents from a reservoir into the vitreous humor.

Plasmalogens from anaerobic bacteria lower inflammatory cytokine expressions, addressing toxicity concerns in conventional colon cancer therapies.

DNA-capped gold nanoparticles bind doxorubicin via intercalation, resolving narrow therapeutic windows by delivering high payloads directly to cancer cells.

Glycyl-glutamine increases brain serotonin levels to treat depression without side effects of SSRIs.

Graphene quantum dot conjugates resolve imaging safety trade-offs by enabling precise cancer cell targeting and fluorescence diagnostics.

Oral bioavailability of the prodrug resolves administration discomfort while maintaining complete amyloid regression.

A pharmaceutical composition combining L-carnitine, troxerutine, and hesperidine to enhance venous health.

Deoxycytidine and cyclosporin H overcome intracellular barriers to improve transduction efficiency while preserving stem cell activity.

Modular inhibitor compounds optimize potency against USP30 while managing synthesis complexity, enabling targeted treatment of cancer and Parkinson's disease.

Concurrent radical polymerization minimizes unreacted allyl groups to resolve compositional homogeneity issues in pharmaceutical polymers.

Segmenting PDE isoforms with selective inhibitors modulates cAMP levels to treat neurodegenerative disorders while minimizing seizure risks.

5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride treats inflammatory bowel disease.